Abstract: The present technology provides methods of preventing or treating an ischemia-reperfusion injury, such as acute myocardial infarction injury, in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and a second active agent to subjects in need thereof.

Abstract: The disclosure provides methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia, and/or reducing the likelihood or severity of Friedreich's ataxia. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to e.g., reduce oxidative stress, increase mitochondrial metabolism, or a combination thereof.

Abstract: The invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.

Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of an MPP, and/or naturally or artificially occurring variants or analogues of an MPP, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide such as D-Arg-2?6?-Dmt-Lys-Phe-NH2).

Abstract: The disclosure provides methods of reducing MMP-9 expression and/or MMP-9 activity in a mammalian subject. The disclosure also provides methods of increasing TIMP-1 expression and/or TIMP-1 activity in a mammalian subject. The methods comprise administering a therapeutically effective amount of an aromatic-cationic peptide to a subject in need thereof.

Abstract: The invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods provide administering aromatic-cationic peptides in effective amounts to prevent or treat an anatomic zone of no re-flow in mammalian subjects. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.

Abstract: The disclosure provides methods and compositions for increasing SERCA2a expression levels in a mammalian subject in need thereof. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide to subjects in need thereof. In some embodiments, the aromatic-cationic peptide is D-Arg-2?6?-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof such as acetate or trifluoroacetate salt. In some embodiments, the subject has suffered a myocardial infarction.

Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of GLP-1, and/or naturally or artificially occurring variants or analogues of GLP-1, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide such as D-Arg-2?6?-Dmt-Lys-Phe-NH2).

Abstract: This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof, wherein the peptide is D-Arg-2 6-Dmt-Lys-Phe-NH2 (SS-31).

Abstract: The disclosure provides methods of preventing, ameliorating or treating disruption of mitochondrial function and symptoms thereof. The methods provide administering aromatic-cationic peptides in effective amounts to prevent, treat or ameliorate the disruption of mitochondrial oxidative phosphorylation in a cell such as that found in a subject suffering from, or predisposed to a mitochondrial disease or disorder. In some embodiments, the methods comprise administering to a subject suffering from, or at risk for a mitochondrial disease or disorder, an effective amount of an aromatic-cationic peptide to subjects in need thereof.

Abstract: The invention provides methods of treating an obstructive coronary artery disease in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof, and performing a coronary artery bypass graft procedure on the subject.

Abstract: Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and, in some applications, a second active agent, to subjects in need thereof. The present technology relates to the treatment or prevention of atherosclerosis in mammals through the administration of a therapeutically effective amount of aromatic cationic peptides and, in some embodiments, a second active agent.

Abstract: The present disclosure describes an exemplary hybrid client/server architecture that may be utilized leverage the unique capabilities of both remote and local services. Data may be processed in parallel by remote and local processes. Results generated during the parallel processing may be exchanged between remote and local services and used to update results generated by the separate services. The hybrid client/server architecture may be utilized to generate enhanced inferences, hybrid subscriptions base upon local and remote subscriptions, and enhance natural language expression evaluation services.

Abstract: The disclosure provides methods of preventing or treating heart failure in a mammalian subject, reducing risk factors associated with heart failure, and/or reducing the likelihood or severity of heart failure. The disclosure also provides methods of preventing, or treating LV remodeling in a mammalian subject, and/or reducing the likelihood or severity of LV remodeling. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide. In some embodiments, the methods comprise administering to the subject an effective amount of an aromatic cationic peptide to reduce levels of C-reactive protein, tumor necrosis factor alpha, interleukin 6, reactive oxygen species, Nt-pro BNP, and/or cardiac troponin I, and/or reduce expression levels of MLCL AT1 and/or ALCAT 1 in subjects in need thereof.

Abstract: Incorporation of an exogenous large-vocabulary model into rule-based speech recognition is provided. An audio stream is received by a local small-vocabulary rule-based speech recognition system (SVSRS), and is streamed to a large-vocabulary statistically-modeled speech recognition system (LVSRS). The SVSRS and LVSRS perform recognitions of the audio. If a portion of the audio is not recognized by the SVSRS, a rule is triggered that inserts a mark-up in the recognition result. The recognition result is sent to the LVSRS. If a mark-up is detected, recognition of a specified portion of the audio is performed. The LVSRS result is unified with the SVSRS result and sent as a hybrid response back to the SVSRS. If the hybrid-recognition rule is not triggered, an arbitration algorithm is evoked to determine whether the SVSRS or the LVSRS recognition has a lesser word error rate. The determined recognition is sent as a response to the SVSRS.

Abstract: Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and in some applications, a second active agent chemically linked to the peptide, to subjects in need thereof.

Abstract: A finished pharmaceutical product adapted for oral delivery of an aromatic-cationic peptide, wherein the product comprises a therapeutically effective amount of the peptide; at least one pharmaceutically acceptable pH-lowering agent; and at least one absorption enhancer effective to promote bioavailability of the active agent. The product is adapted for use in a method for enhancing the bioavailability of a therapeutic aromatic-cationic peptide delivered orally.

Abstract: Disclosed herein are compositions and methods related to aromatic-cationic peptides. In particular, the compositions and methods relate to aromatic-cationic peptides in conjunction with cytochrome c. In some embodiments, the aromatic-cationic peptide comprises one or more of D-Arg-Tyr-Lys-Phe-NH2 (P-231), DArg-D-Dmt-D-Lys-D-Phe-NH2, and D-Arg-D-Tyr-D-Lys-D-Phe-N H2 (P-2310). In some embodiments, the method relates to increasing cytochrome c reduction, enhancing electron diffusion through cytochrome c, enhancing electron capacity in cytochrome c, and/or inducing novel n-n interactions around cytochrome c.

Abstract: The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition.

Abstract: The disclosure provides methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. More specifically, the disclosure provides a composition for preventing, treating, or ameliorating the symptoms of diabetic macular edema in a mammalian subject in need thereof, comprising: a therapeutically effective amount of a peptide D-Arg-2?6?-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.